The TRANSCEND-T2D-1 trial (NCT06354660) demonstrated HbA1c reductions of 1.7-2.0% and 36.6 lbs mean weight loss in type 2 diabetes participants over 40 weeks
These studies will provide valuable insights into the long-term efficacy, safety, and tolerability of this triple-hormone receptor agonist, as well as its potential impact on cardiovascular outcomes
As clinical use of GLP-1 receptor agonists continues to expand, understanding how these medications alter the subjective/interoceptive effects of alcohol will be critical for optimizing their utility in AUD
PlexusDx's personalized approach helps identify whether you're likely to respond well
Allison Schneider, a spokesperson for Novo Nordisk, the manufacturer of Ozempic and Wegovy, said in a statement that the company is aware of several compounding pharmacies claiming to offer compounded semaglutide and is taking action against these entities," though she did not provide further details